ASCENT
Analysis of screen-detected lung cancers’ genomic traits

ASCENT is an observational study. An estimated 529 participants with lung cancer screen-detected through the SUMMIT study or the NHS Targeted Lung Health Check programme will be recruited across two L [...]

Area: Lung cancer

Phase: Observational trials

Status: Active (recruiting)

DARWIN 1
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

DARWIN1 is an open label, multi-centre single arm phase II trial for eligible NSCLC patients with sensitising EGFR mutation or HER2 mutations, who relapse and have multi-region sequencing data of the [...]

Area: Lung cancer

Phase: Phase II

Status: Closed

DARWIN 2
Deciphering Anti-tumour Response and Resistance With INtratumour Heterogeneity

DARWIN II is a phase II multi-centre non-randomised trial for NSCLC patients to study tumour heterogeneity using genomic analysis. The trial will only be opened in sites participating in the TRACERx s [...]

Area: Lung cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

EARL
Electrocautery Ablation for the Prevention of Lung Cancer

EARL is a phase II/III multicentre 2:1 randomised controlled trial to evaluate the effectiveness of electrocautery (EC) in the treatment of high-grade lesions of the lung. All patients consented/regis [...]

Area: Lung cancer

Phase: Phase II/III

Status: Closed

HIT-Meso
Hemithoracic irradiation with proton therapy in malignant pleural mesothelioma

Phase III randomised controlled trial for patients with unilateral malignant pleural mesotheliomaEligible patients are randomised (1:1) to receive either proton beam therapy (PBT) or standard active s [...]

Area: Lung cancer

Phase: Phase III

Status: Active (recruiting)

IDEAL-CRT
A phase I/II trial of concurrent chemoradiation with dose-escalated radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer

IDEAL-CRT is a multicentre phase I/II trial of concurrent chemoradiation with dose-escalated radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer.

Area: Lung cancer

Phase: Phase I/II

Status: Closed

Lung Trans
Biomarker Analysis to Predict Response in Lung Cancer

Lung Trans is a non-interventional laboratory study.

Area: Lung cancer

Phase: Laboratory study

Status: In set-up (funded)

MESO-02
A phase I/II study of first line ganetespib with pemetrexed/Cisplatin in patients with malignant pleural mesothelioma

A phase I/II study of first line ganetespib with pemetrexed-platinum in patients with malignant pleural mesothelioma. Phase I follows a 3+3 dose escalation design (cisplatin patients) and an accelerat [...]

Area: Lung cancer

Phase: Phase I/II

Status: Closed

PEACE
The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study

Posthumous Evaluation of Advanced Cancer Environment Study is a multi-centre prospective observational study

Area: Lung cancer

Phase: Tissue collection

Status: Active (recruiting)

SARON
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer. A randomised phase III trial

SARON is a randomised, controlled phase II trial of systemic anti-cancer therapy (SACT) versus SACT+ radiotherapy in patients with oligometastatic (1-5 metastases) non-small cell lung cancer (NSCLC) p [...]

Area: Lung cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

Study 15
A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychlroquine with carboplatin/etoposide therapy in extensive stage small cell lung cancer (SCLC)

Study 15 is a multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine (HCQ) versus carboplatin/etoposide therapy alone in small cell lung cancer.

Area: Lung cancer

Phase: Phase II

Status: Closed

SUMMIT
Cancer screening study with or without low dose lung CT to validate a multi-cancer early detection test

SUMMIT is a Prospective cohort study involving patients who smoke and used to smoke in the past 20 years. This study will examine ways to detect lung cancer before there are any symptoms, when treatme [...]

Area: Lung cancer

Phase: Observational trials

Status: In follow-up (non-recruiting)

TIMELY
Trial of afatinib in suspected or confirmed mutant EGFR lung cancer patients unfit for chemotherapy

TIMELY was an open label single arm phase II trial using an irreversible second generation EGFR inhibitor, afatinib. Trial afatinib treatment was given to non-small cell lung cancer (NSCLC) patients w [...]

Area: Lung cancer

Phase: Phase II

Status: Closed

TRACERx
TRAcking non small cell lung Cancer Evolution through therapy (Rx)

TRACERx is a prospective observational cohort study of patients with non-small cell lung cancer (NSCLC), in which translational research is the fundamental aspect of the study.

Area: Lung cancer

Phase: Observational trials

Status: Active (recruiting)

TRACERx EVO
TRAcking thoracic Cancer Evolution through therapy (Rx) EVO

TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC),small cell lung cancer (SCLC) and pleura [...]

Area: Lung cancer

Phase: Observational trials

Status: Active (recruiting)